Organisation
Pfizer/ BioNTech
Country
US/Germany
mRNA vaccine
What type is it?
How effective
is it?
95% efficacy a week after
receiving the second shot. Pfizer
says it is only 52% effective after
the first dose, but the Joint
Committee on Vaccination and
Immunisation (JCVI) says this may
rise to 90% after 21 days. 40
million doses ordered. Currently
being rolled out across the UK
What’s the
dosing regime?
Clinical trials involved two doses
21 days apart. UK is currently
stretching this to 12 weeks
Organisation
Oxford University/ AstraZeneca
Country
UK
Adenovirus vector vaccine
(delivered using a chimp
cold virus)
What type is it?
How effective
is it?
70.4% efficacy, 14 days after
receiving the second dose. May
have up to 90% efficacy when
given as a half dose followed by
a full dose. No severe disease or
hospitalisations in anyone who
received the vaccine. 100 million
doses ordered. Currently being
rolled out across the UK
What’s the
dosing regime?
Two doses, 4-12 weeks apart
Organisation
Moderna
Country
US
mRNA vaccine
What type is it?
Phase 3 trial results suggest an
efficacy of 94.1%. The UK has
ordered 17 million doses, to be
delivered in March or April
How effective
is it?
Two doses, 28 days apart
What’s the
dosing regime?
Organisation
Novavax
Country
US
Protein adjuvant vaccine
(boosts immune system)
What type is it?
Phase 3 trials suggest 89.3%
efficacy. 60 million doses
ordered
How effective
is it?
Two doses
What’s the
dosing regime?
Organisation
Janssen
(part of Johnson&Johnson)
Country
US
Adenovirus vector vaccine
What type is it?
How effective
is it?
72% efficacy in preventing mild
to moderate cases Covid in US
trials, but 66% efficacy observed
in international trials. 85%
efficacy against severe illness,
and 100% protection against
hospitalisation and death. 30
million doses ordered
One dose
What’s the
dosing regime?
What’s the
dosing regime?
Maker
Country
What type is it?
How effective is it?
95% efficacy a week after receiving the second shot. Pfizer says it is only 52% effective after the first dose, but the Joint Committee on Vaccination and Immunisation (JCVI) says this may rise to 90% after 21 days. 40 million doses ordered. Currently being rolled out across the UK
Clinical trials involved two doses 21 days apart. UK is currently stretching this to 12 weeks
Pfizer/ BioNTech
mRNA vaccine
US/Germany
Oxford University/
AstraZeneca
UK
Adenovirus vector
vaccine (it uses the
virus that causes
colds in chimpanzees)
70.4% efficacy, 14 days after receiving the second dose. May have up to 90% efficacy when given as a half dose followed by a full dose. No severe disease or hospitalisations in anyone who received the vaccine. 100 million doses ordered. Currently being rolled out across the UK
Two doses, 4-12 weeks apart
Two doses, 28 days apart
Phase 3 trial results suggest an efficacy of 94.1%. The UK has ordered 17 million doses, to be delivered in March or April
Moderna
US
mRNA vaccine
Novavax
US
Protein adjuvant
vaccine (boosts
immune system)
Two doses
Phase 3 trials suggest 89.3% efficacy. 60 million doses ordered
72% efficacy in preventing mild to moderate cases Covid in US trials, but 66% efficacy observed in international trials. 85% efficacy against severe illness, and 100% protection against hospitalisation and death.
30 million doses ordered
Janssen
Pharmaceuticals
(part of Johnson&
Johnson)
US
Adenovirus vector
vaccine
One dose